Observational studyMedicine2025
Analysis of changes in respiratory tract infections in a tertiary grade A hospital in Zhangjiakou area from 2018 to 2024.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trend ofIJID regions · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We aimed to analyze the epidemiological characteristics and pathogen trends of common respiratory infections in a tertiary hospital in Zhangjiakou from 2018 to 2024. We retrospectively studied patients who underwent screening for 11 common respiratory pathogen antibodies at the First Affiliated Hospital of Hebei North University between January 1, 2018, and December 31, 2024. Serum-specific Immunoglobulin M antibodies were detected using indirect immunofluorescence assays, and annual data from 2018 to 2024 were compared. Among 35,665 patients, 10,531 (29.53%) were positive for at least 2 pathogen. The lowest positivity rate was observed in 2020 (23.47%, 841/3584), while the highest was observed in 2023 (38.58%, 3165/8204). Mycoplasma pneumoniae exhibited the highest positivity rate (11.99%, 4278/35,665), followed by influenza B virus (10.83%, 3861/35,665). Influenza A virus, respiratory syncytial virus, parainfluenza virus, Chlamydia pneumoniae, Legionella pneumophila, Coxsackie A virus, Coxsackie B virus, Echovirus, and adenovirus had relatively low positivity rates, ranging from 0.88% to 4.97%. Positive cases were stratified as follows: 0 to <3 years (13.32%, 1403/10,531), 3 to <6 years (17.52%, 1845/10,531), 6 to <12 years (18.35%, 1932/10,531), 12 to <18 years (6.37%, 671/10,531), 18 to <60 years (15.86%, 1670/10,531), and ≥60 years (28.58%, 3010/10,531). The proportion of patients <12 years significantly decreased by 2024 compared to 2018 (P < .001), while the proportion of patients significantly increased in the ≥60 group (P < .001). Single-pathogen infection was the predominant type (68.73%, 7238/10,531), followed by dual-pathogen infections (23.26%, 2450/10,531). The proportion of single-pathogen cases decreased from 75.59% in 2018 to 60.32% in 2023, rebounding to 74.36% in 2024. On the contrary, the number of dual-pathogen cases increased from 18.46% in 2018 to 27.65% in 2023, and then decreased to 21.67% in 2024 (P < .001). From 2018 to 2024, the epidemiological features of common respiratory pathogens exhibited significant temporal variations, with reduced positivity rates during the Coronavirus Disease 2019 pandemic and a sharp resurgence after the pandemic. Routine pathogen screening provides critical data for regional respiratory infection prevention and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.